IMPACT OF ONCE-WEEKLY SUBCUTANEOUS SEMAGLUTIDE 2.4 MG ON METABOLIC SYNDROME IN THE 2-YEAR, RANDOMIZED CONTROLLED STEP 5 TRIAL

Metabolic syndrome (MetS) is associated with an increased risk of cardiovascular disease and type 2 diabetes. Obesity is a key driver of MetS. In the STEP 5 trial, treatment with once-weekly subcutaneous semaglutide 2.4 mg resulted in 15.2% weight loss after 104 weeks vs 2.6% with placebo. This post hoc analysis of STEP 5 investigated the effect of 2 years of treatment with semaglutide on MetS.